Novel molecular targets for prostate cancer therapy.
The treatment options available for advanced prostate cancer are increasing. These improved therapies are the result of research involving cellular targets other than DNA proliferation. For example, therapy directed against the intracellular matrix has yielded clinical responses in patients. Other novel targets are being investigated. This review examines both laboratory and clinical advances using cell structure, growth factors, differentiating agents, angiogenesis, metastasis, and the cell cycle in the treatment of prostate cancer.
Kamradt
J M
JM
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor 41809-0946, USA.
Pienta
K J
KJ
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D004273:DNA, Neoplasm / Q000187:drug effects; D005109:Extracellular Matrix / Q000187:drug effects; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008967:Molecular Biology; D009362:Neoplasm Metastasis / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D006133:Growth Substances